Discover all the brand names or Trade names of generic drug called Ranitidine. This serves as a crucial reference for healthcare professionals, patients, caregivers, and anyone looking to ...

Patients received either Protonix 10 mg, 20 mg, or 40 mg delayed-release tablets once daily or ranitidine 150 mg twice daily. Protonix 20 mg and 40 mg was significantly superior to ranitidine at ...

A jury in an Illinois state court found on Monday that British pharmaceutical giant GSK’s (NYSE:GSK) discontinued heartburn ...

He was given prescriptions for diphenhydramine hydrochloride 50 mg orally four times daily and ranitidine hydrochloride 150 mg orally twice daily for 10 days, in addition to the prednisone regimen ...

(Bloomberg) -- Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac ...

and independent laboratories shows that one ranitidine 300 mg tablet can contain tens of thousands of nanograms (ng) of NDMA, greatly exceeding the FDA’s daily acceptable intake limit of 96 ng ...

A Chicago jury failed to reach a verdict Sept. 18 over claims that heartburn drug Zantac causes cancer, Reuters exclusively reported. The case, brought by Illinois resident Ronald Kimbrow ...

The brand of this medicine does not contain ranitidine, a medicine that was withdrawn from market in the United States. Zantac 360 Famotidine may also be used for purposes not listed in this ...

此车系在当前城市暂无经销商信息。 此车系在当前城市暂无经销商信息。

GSK plc (LSE/NYSE: GSK), a leading global pharmaceutical company, has reached a confidential settlement in a Zantac (ranitidine) related prostate cancer lawsuit filed by Mr. Isaac Dixon in ...

GSK Plc shares rose on Wednesday, buoyed by a US court’s decision to review whether evidence supporting claims that heartburn drug Zantac causes cancer is scientifically sound. The British ...

Hung jury in latest Zantac cancer trial in Chicago Boehringer Ingelheim only defendant after settlements with GSK, Pfizer FDA pulled Zantac in 2020 over NDMA carcinogen concerns Sept 18 (Reuters ...